Abbott Laboratories

• ABT Stock Price 24h change: -0.21%. From 126.18 USD to 125.92 USD. (As of Jan 9, 2026; NYSE). The price showed minor consolidation as the market anticipates the Q4 2025 earnings release on January 22.
• From a technical perspective, the stock is in a "stagnant consolidation phase" with a neutral-to-bearish short-term bias. The 14-day RSI stands at 44.32 (Neutral/Sell), and while the 200-day SMA ($125.54) provides immediate support, the 50-day SMA ($126.12) currently acts as a ceiling, indicating a lack of clear momentum.
• Abbott announced its Q4 2025 financial results will be released on Jan 22, 2026, with investors focusing on FY2026 guidance following a steady FY2025 performance.
• The FreeStyle Libre 3 Plus sensor achieved a major milestone by securing public funding coverage across every province in Canada, significantly expanding its market reach.
• Sumitomo Mitsui Trust Group increased its stake in ABT by 1.3%, holding over 4 million shares, signaling continued institutional confidence in the company's long-term value.
• Roughly 15,000 nurses across major New York City hospital systems began a massive strike on Jan 12, 2026, over staffing and safety disputes, threatening to disrupt regional healthcare operations.
• The UK government launched the Health Data Research Service (HDRS) with £600 million in funding, appointing former Moderna executive Dr. Melanie Ivarsson as CEO to accelerate medical breakthroughs.

• ABT Stock Price 24h change: -0.21%. From 126.18 USD to 125.92 USD. The minor decline reflects a period of consolidation as investors await the upcoming Q4 2025 earnings report scheduled for late January.
• Technical analysis indicates a "neutral horizontal trend." ABT is currently trading within a rectangle formation between support at $121 and resistance at $135. With an RSI of 44.32 and a MACD of -0.15, the stock shows slight selling pressure but remains stable above its 200-day simple moving average ($125.54), suggesting balanced long-term sentiment.
• Bernstein raised Abbott's price target to $154 from $150 on January 9, maintaining an "Outperform" rating due to sustained confidence in its cardiovascular and diabetes portfolios.
• Abbott announced a dividend increase to $0.63 per share (up from $0.59), with the next payment scheduled for February 13, 2026, marking its 54th consecutive year of payout growth.
• The company confirmed it will release its Q4 2025 financial results on January 22, 2026, with analysts anticipating an EPS of approximately $1.50.
• The S&P 500 Healthcare Index gained 1.5% this week; however, major players like AbbVie faced pressure after flagging a $1.3 billion charge related to R&D and milestones.
• Novo Nordisk officially launched a pill version of its weight-loss drug Wegovy in the U.S. for $149/month, signaling intensifying competition in the obesity treatment market.